Latest News and Press Releases

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially...

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology  Continued progress with growing global patent portfolio to over 80 issued patents...

THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...

On-demand video webcast now available here THE WOODLANDS, TX, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...

THE WOODLANDS, TX, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...

Live video webcast on Wednesday, January 22nd at 4:00 PM ET THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical...

79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected...

THE WOODLANDS, TX, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...

Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction...

THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...